Share Talk Weekly Small Cap Movers & Shakers, Saturday 23rd July 2022

These are some of the most significant movers on Aim in the last week.

Overall, AIM’s top shares enjoyed a good week. The junior market 100 indexes rose 0.5% in the past five days to 4,386. This was compared to a flat Footsie performance.

Tirupati Graphite’s (AIM: TGR) stock price jumped 52% to 36p following its announcement that it will increase its primary flake graphite manufacturing capacity in Madagascar by 30,000 tonnes per year by September 2022. As the junior had previously stated, it was having difficulties reaching production targets in the first quarter due to adverse weather conditions that made transporting the mined ore to the plant difficult. This seemed like confirmation that things are improving quickly.

Stanley Gibbons, the owner of the iconic stamp shop at 399 The Strand in London, is also rising after it announced plans to delist AIM after a turbulent 20 years as a public company. Phoenix Asset Management Partners asked it to do so on behalf of Phoenix SG, the largest investor in the company. Phoenix SG is 58% owner of the philatelic and coins specialist.

It is considered cost-effective to leave the market. This move will help reduce “negative operational effects on the business”. Investors who don’t want to own unlisted stock will be able to sell their shares at 1.5p per share. This was the closing price last night.

Poolbeg Pharma PLC, (AIM: POLB) was a star on AIM this week when it launched a challenge trial for the treatment of severe influenza.

It normally conducts trials for other pharmaceutical groups, so the fact that this study is on one of its drugs marks a significant milestone for the Dublin-based company. The trial, POLB001, was initiated by researchers on Friday, July 22nd.

A first data readout is expected to take place in the fourth quarter. The group will then look for early monetisation opportunities through partnerships and licensing agreements. Poolbeg stated that success would open the door to potential applications beyond severe influenza.

Jeremy Skillington, chief executive, explained that POLB 001’s unique mechanism of action to reduce inflammation in the body makes it immune to any strain of the virus. It also has the potential for expansion to other diseases.

“As such it could offer additional opportunities to create significant value beyond severe flu for the company as well as our shareholders. After briefly touching 5.3p, shares rose 5% to 4.9p during the week.

Mirriad Advertising (AIM: MIRI) fell 40% after it revealed that its global turnover had dropped 50% to PS577,000 for the first half. In line with last year’s guidance, Guidance calls for PS2mln in revenue in 2022. This is because it has shifted spending away from China. The digital advertising company will double its efforts in the US market. Its turnover increased 57% in the first half.

Alliance Pharma (AIM: APH) fell from its all-time highs, as key brands Amberen and Nizoral saw a lower first half. The shares fell to 97.5p from 123p in March after hitting 123p in March.

Corcel (AIM: CRCL) a battery metals investor, dropped following fundraising that reached £600,000. This included a £336,000 placement at a price of 0.4p.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.